Small intravenous devices (IVDs) commonly used in the hand or arm do not need to be moved routinely every 3 days. A randomized controlled trial comparing regular relocation with relocation on clinical indication, published in the open access journal BMC Medicine, found that rates of complications were the same for both regimens.
Claire Rickard, from Griffith University, Australia, worked with a team of researchers to carry out the study with 362 patients at Launceston General Hospital, Tasmania. She said, “Recommended timelines for routine resite have been extended over the past three decades from 24 to 72 hours. Currently, 72- to 96-hour resite is recommended. Even with these extended durations, such policies still cause increased workload in hospitals, where the task of removing and replacing well-functioning IVDs generally falls to busy nursing and junior medical staff. Our results indicate that the average duration of IV therapy is 5-6 days and that many catheters can remain complication-free for this period, or even longer”.
The researchers found that complication rates between the groups were not significantly different. The policy of resite on clinical indication led to one in two patients needing only a single cannula to receive treatment, whereas a 3-day change policy resulted in one in five patients having this scenario, with the rest requiring multiple cannulations and therefore additional pain and inconvenience. According to Rickard, “The routine resite of peripheral IVDs increases patient discomfort and healthcare costs, but does not reduce IVD complications as has traditionally been thought”.
Notes to Editors
1. Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
Claire M Rickard, Damhnat McCann, Jane Munnings and Matthew R McGrail
BMC Medicine 2010, 8:53 doi:10.1186/1741-7015-8-53
Article available at the journal website: http://www.biomedcentral.com/1741-7015/8/53/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central’s open access policy.
2. BMC Medicine – the flagship medical journal of the BMC series – publishes original research articles, commentaries and reviews in all areas of medical science and clinical practice. To be appropriate for BMC Medicine, articles need to be of outstanding quality, broad interest and special importance. BMC Medicine (ISSN 1741-7015) is indexed/tracked/covered by PubMed, MEDLINE, BIOSIS, CAS, EMBASE, Scopus, Current Contents, Thomson Reuters (ISI) and Google Scholar.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
